Skip to content

DNA Methylation for Screening Uterine Cervical Lesions: A Case-control Study

Utilization of DNA Methylation in the Screening of Uterine Cervical Lesions: A Case-control Study

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT03961191
Enrollment
300
Registered
2019-05-23
Start date
2019-05-22
Completion date
2020-05-22
Last updated
2019-05-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

DNA Methylation, High Grade Squamous Intraepithelial Lesions, Low Grade Squamous Intraepithelial Lesions, Uterine Cervical Cancer

Brief summary

The primary objective of this study is to compare the testing of DNA methylation, high-risk HPV subtypes, and cytology with the definite histological results in a case-control study, so as to determine the accuracy of DNA methylation in the screening of uterine cervical lesions. This study will include 300 patients with definite histological results, with 100 of cervical inflammation or low grade squamous intraepithelial lesions (LSIL), 100 of high grade squamous intraepithelial lesions (HSIL), and 100 of uterine cervical cancer. All the cervical specimens of cytology collected in the clinical settings will be utilized for the testing of DNA methylation, high-risk HPV subtypes and thin prep liquid-based cytology test (TCT). The sensitivity, specificity, positive predictive value and negative predictive value were calculated based on the known histological results. The differences of DNA methylation with high-risk human papillomavirus (HPV) and TCT will also be analyzed. The testing of DNA methylation will be performed with the methylation-specific polymerase chain reaction (PCR). The TCT and HPV testing will be performed with the Roche kits.

Interventions

DIAGNOSTIC_TESTDNA methylation

DNA methylation for the cervical cytology

DIAGNOSTIC_TESThigh-risk HPV

High-risk HPV testing for the cervical cytology

DIAGNOSTIC_TESTTCT

Thin prep liquid-based cytology test for the cervical cytology

Sponsors

Lei Li
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Confirmed cervical histology within one month when collecting cervical cytology * Aged 18 years or older * Signed an approved informed consents

Exclusion criteria

* Not meeting any of the inclusion criteria

Design outcomes

Primary

MeasureTime frameDescription
Sensitivity of DNA methylation1 yearsSensitivity of DNA methylation compared with histological results for the differentiation of cervical cancer and HSIL
Specificity of DNA methylation1 yearsSpecificity of DNA methylation compared with histological results for the differentiation of cervical cancer and HSIL

Secondary

MeasureTime frameDescription
Positive predictive value of DNA methylation1 yearPositive predictive value of DNA methylation compared with histological results for the differentiation of cervical cancer and HSIL
Negative predictive value of DNA methylation1 yearNegative predictive value of DNA methylation compared with histological results for the differentiation of cervical cancer and HSIL
Correlation coefficient of DNA methylation with other screening methods1 yearCorrelation coefficient of DNA methylation with high-risk HPV and TCT results

Countries

China

Contacts

Primary ContactLei Li, M.D.
lileigh@163.com+8613911988831

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026